GB0100119D0 - Materials and methods relating to protein aggregation in neurodegenerative disease - Google Patents
Materials and methods relating to protein aggregation in neurodegenerative diseaseInfo
- Publication number
- GB0100119D0 GB0100119D0 GBGB0100119.7A GB0100119A GB0100119D0 GB 0100119 D0 GB0100119 D0 GB 0100119D0 GB 0100119 A GB0100119 A GB 0100119A GB 0100119 D0 GB0100119 D0 GB 0100119D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- protein aggregation
- materials
- neurodegenerative disease
- methods relating
- prognostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0100119.7A GB0100119D0 (en) | 2001-01-03 | 2001-01-03 | Materials and methods relating to protein aggregation in neurodegenerative disease |
| AT02734847T ATE548453T1 (de) | 2001-01-03 | 2002-01-02 | Material und methoden, involviert in die protein- aggregation neurodegenerativer krankheiten |
| CA2433535A CA2433535C (en) | 2001-01-03 | 2002-01-02 | Materials and methods relating to protein aggregation in neurodegenerative disease |
| JP2002559452A JP4580618B2 (ja) | 2001-01-03 | 2002-01-02 | 神経変性疾患におけるタンパク質凝集に関する材料および方法 |
| EP02734847A EP1348029B1 (en) | 2001-01-03 | 2002-01-02 | Materials and methods relating to protein aggregation in neurodegenerative disease |
| PT02734847T PT1348029E (pt) | 2001-01-03 | 2002-01-02 | Materiais e métodos relativos a agregação de proteínas em doenças neurodegenerativas |
| ES02734847T ES2382457T3 (es) | 2001-01-03 | 2002-01-02 | Materiales y procedimientos relacionados con la agregación de proteínas en enfermedades neurodegenerativas |
| HK03108778.8A HK1056574B (en) | 2001-01-03 | 2002-01-02 | Materials and methods relating to protein aggregation in neurodegenerative disease |
| DK02734847.3T DK1348029T3 (da) | 2001-01-03 | 2002-01-02 | Materialer og fremgangsmåder involveret i proteinaggregering i neurodegenerative sygdomme |
| PCT/GB2002/000005 WO2002059150A2 (en) | 2001-01-03 | 2002-01-02 | Materials and methods relating to protein aggregation in neurodegenerative disease |
| AU2002217310A AU2002217310B2 (en) | 2001-01-03 | 2002-01-02 | Materials and methods relating to protein aggregation in neurodegenerative disease |
| US10/451,367 US7834237B2 (en) | 2001-01-03 | 2002-01-02 | Materials and methods relating to protein aggregation in neurodegenerative disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0100119.7A GB0100119D0 (en) | 2001-01-03 | 2001-01-03 | Materials and methods relating to protein aggregation in neurodegenerative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB0100119D0 true GB0100119D0 (en) | 2001-02-14 |
Family
ID=9906201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0100119.7A Ceased GB0100119D0 (en) | 2001-01-03 | 2001-01-03 | Materials and methods relating to protein aggregation in neurodegenerative disease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7834237B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1348029B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4580618B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE548453T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002217310B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2433535C (cg-RX-API-DMAC7.html) |
| DK (1) | DK1348029T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2382457T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0100119D0 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1348029E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002059150A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0104685D0 (en) * | 2001-02-26 | 2001-04-11 | Leuven K U Res & Dev | Tau-opathy model |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| WO2004007722A2 (en) * | 2002-07-12 | 2004-01-22 | Axon Neuroscience Forschungs- Und Entwicklungs Gmbh | Transgenic animal expressing alzheimer’s tau protein |
| EP1516930A1 (en) * | 2003-09-16 | 2005-03-23 | Georg-August Universität Göttingen | Cellular model of tauopathies for lead identification and drug discovery |
| DE602005016537D1 (de) * | 2004-03-31 | 2009-10-22 | Anges Mg Inc | Testverfahren zur identifizierung eines kandidatenarzneistoffs |
| ES2770067T3 (es) | 2004-05-11 | 2020-06-30 | Ncardia Ag | Descubrimiento de fármacos basado en células diferenciadas in vitro |
| JP5186212B2 (ja) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| WO2007066809A1 (ja) * | 2005-12-06 | 2007-06-14 | Tokyo Metropolitan Organization For Medical Research | タンパク質重合体の重合核となりうるタンパク質又はその重合体が導入された細胞及びその製造法 |
| DK2004155T3 (en) | 2006-03-29 | 2018-04-30 | Wista Lab Ltd | PROTEIN AGGREGATION INHIBITORS |
| CN104119294B (zh) | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
| PT2954932T (pt) | 2007-10-03 | 2018-12-12 | Wista Lab Ltd | Utilização terapêutica de diaminofenotiazinas |
| WO2012106363A2 (en) | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| KR101888713B1 (ko) | 2011-02-11 | 2018-08-14 | 위스타 레보레이토리스 리미티드 | 페노티아진 디아미늄 염 및 이의 용도 |
| WO2012162179A1 (en) | 2011-05-20 | 2012-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
| PL3487505T3 (pl) | 2016-07-25 | 2023-10-09 | Wista Laboratories Ltd. | Podawanie i dawkowanie diaminofenotiazyn |
| CN111094327A (zh) * | 2017-08-16 | 2020-05-01 | Lgv1有限公司 | Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型 |
| CN113874078B (zh) | 2019-04-05 | 2025-05-06 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CN113943766B (zh) * | 2021-11-26 | 2024-01-26 | 守正创新生物科技(天津)有限公司 | 一种抗糖化寡肽-5(AdP)的制备及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE569430A (cg-RX-API-DMAC7.html) | 1957-07-17 | |||
| GB8724412D0 (en) | 1987-10-19 | 1987-11-25 | Medical Res Council | Protein |
| US5571666A (en) | 1988-10-28 | 1996-11-05 | Oklahoma Medical Research Foundation | Thiazine dyes used to inactivate HIV in biological fluids |
| JPH0725786A (ja) | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| US5912410A (en) | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
| CA2110488A1 (en) | 1991-07-10 | 1993-01-21 | Franceska Fieuws | Fluorochemical water- and oil-repellent treating compositions |
| WO1993003369A1 (en) | 1991-08-01 | 1993-02-18 | Voorheis Paul H | Diagnostic method for alzheimer's disease |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| GB9316727D0 (en) | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
| GB9317193D0 (en) | 1993-08-18 | 1993-10-06 | Zeneca Ltd | Method |
| FR2722695B1 (fr) | 1994-07-22 | 1997-04-25 | Demic Lab Sa | Ustensile de badigeonnage cutane par frottement a usage medical |
| WO1996004915A1 (en) | 1994-08-08 | 1996-02-22 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
| US5898094A (en) | 1996-10-21 | 1999-04-27 | University Of South Florida | Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes |
| WO1999062548A1 (en) | 1998-06-01 | 1999-12-09 | Advanced Research And Technology Institute | Methods and compositions for diagnosing tauopathies |
| DE19920514A1 (de) * | 1999-05-05 | 2000-11-16 | Boehringer Ingelheim Pharma | Methoden zur Auffindung von Proteasen, die spezifisch membrangebundene Substrate spalten |
| WO2001053340A2 (en) | 2000-01-21 | 2001-07-26 | Pharmacia & Upjohn Company | Transgenic mouse model of human neurodegenerative disease |
| JP2001352860A (ja) * | 2000-06-15 | 2001-12-25 | Inst Of Physical & Chemical Res | 老年期痴呆症で生じる神経原線維変化を示すマウス |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| US20030217370A1 (en) | 2002-05-16 | 2003-11-20 | Giasson Benoit I. | Transgenic animal expressing alpha-synuclein and uses thereof |
| US6953974B2 (en) * | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| WO2006032879A2 (en) | 2004-09-23 | 2006-03-30 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
-
2001
- 2001-01-03 GB GBGB0100119.7A patent/GB0100119D0/en not_active Ceased
-
2002
- 2002-01-02 EP EP02734847A patent/EP1348029B1/en not_active Expired - Lifetime
- 2002-01-02 WO PCT/GB2002/000005 patent/WO2002059150A2/en not_active Ceased
- 2002-01-02 PT PT02734847T patent/PT1348029E/pt unknown
- 2002-01-02 US US10/451,367 patent/US7834237B2/en not_active Expired - Lifetime
- 2002-01-02 DK DK02734847.3T patent/DK1348029T3/da active
- 2002-01-02 ES ES02734847T patent/ES2382457T3/es not_active Expired - Lifetime
- 2002-01-02 CA CA2433535A patent/CA2433535C/en not_active Expired - Lifetime
- 2002-01-02 JP JP2002559452A patent/JP4580618B2/ja not_active Expired - Lifetime
- 2002-01-02 AT AT02734847T patent/ATE548453T1/de active
- 2002-01-02 AU AU2002217310A patent/AU2002217310B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002217310B2 (en) | 2007-09-20 |
| JP2004531224A (ja) | 2004-10-14 |
| WO2002059150A2 (en) | 2002-08-01 |
| PT1348029E (pt) | 2012-06-15 |
| DK1348029T3 (da) | 2012-05-29 |
| CA2433535A1 (en) | 2002-08-01 |
| CA2433535C (en) | 2011-02-15 |
| EP1348029B1 (en) | 2012-03-07 |
| HK1056574A1 (en) | 2004-02-20 |
| ES2382457T3 (es) | 2012-06-08 |
| US20040078835A1 (en) | 2004-04-22 |
| JP4580618B2 (ja) | 2010-11-17 |
| WO2002059150A3 (en) | 2002-12-05 |
| EP1348029A2 (en) | 2003-10-01 |
| US7834237B2 (en) | 2010-11-16 |
| ATE548453T1 (de) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1348029T3 (da) | Materialer og fremgangsmåder involveret i proteinaggregering i neurodegenerative sygdomme | |
| WO2005061545A3 (en) | Nogoa antibodies for the treatment of alzheimer disease | |
| EP1409544A4 (en) | HUMAN DR4 ANTIBODIES AND ITS APPLICATIONS | |
| PT1625403E (pt) | Método para a previsão, diagnóstico e diagnóstico diferencial de doença de alzheimer | |
| AU8448301A (en) | Remedies for heart failure | |
| CR8108A (es) | Tratamiento con anticuerpos anti-vegf | |
| FI963101A7 (fi) | Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut | |
| WO2009027105A3 (en) | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders | |
| DE69841653D1 (de) | Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten | |
| WO2000078813A3 (en) | Huntington disease cellular model: stably transfected pc12 cells expressing mutant huntingtin | |
| ATE522230T1 (de) | Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit | |
| WO2002046767A3 (en) | Diagnosis and treatment of alzheimer's disease | |
| PL350620A1 (en) | Diagnosis of a person's risk for developing atherosclerosis or diabetic retinopathy | |
| EP1321153A4 (en) | DRUG SUBSTANCES INTENDED FOR INTERSTITIAL PNEUMONIA, METHOD OF CONSTRUCTING AN ANIMAL MODEL OF THE DISEASE, AND SCREENING METHOD USING THE SAME | |
| WO2003036261A3 (en) | Drug development by rapid neuroimaging of neural cells | |
| IT1299201B1 (it) | Fibroblasti modificati geneticamente e loro uso | |
| Caterson | Immunological aspects of markers of joint disease | |
| WO2006029838A3 (en) | Secreted polypeptide species involved in alzheimer’s disease | |
| IL172690A0 (en) | Methods for the diagnosis and prognosis of alzheimer's disease | |
| WO2002074921A3 (en) | Methods for isolating proteins expressed by dendritic cells | |
| AU2001289930A1 (en) | Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis | |
| WO2004064768A3 (en) | Animal model for alzheimer's disease | |
| AU2002316158A1 (en) | Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents | |
| EP1573048A4 (en) | IN CANCER EXPRESSED BRUSH SPECIFIC PROTEIN AND METHOD OF USE THEREOF | |
| PT1496884E (pt) | Associacao de um antitrombotico e de aspirina e sua utilizacao no tratamento das doencas tromboticas aterosclerosas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |